Comparison of intravenous thrombolysis agents for acute ischemic stroke: a systematic review and network meta-analysis
Vergleich intravenöser Thrombolysemittel beim akuten ischämischen Schlaganfall: systematische Übersicht und Netzwerk-Metaanalyse
Frontiers in Pharmacology · 05.11.2026 · 17
DOI: 10.3389/fphar.2026.1884696 ↗Auf einen Blick
19 RCTs mit 14.464 Patient:innen verglichen fünf IVT-Mittel und Placebo. rPA und TNK waren mit besserer funktioneller Erholung verbunden als rt-PA; rhPro-UK senkte das SICH-Risiko gegenüber TNK.
Fragestellung
Wie unterscheiden sich Wirksamkeit und Sicherheit der intravenösen Thrombolysemittel bei akutem ischämischem Schlaganfall innerhalb von 4,5 h nach Symptombeginn?
Methode
Frequentistische Netzwerk-Metaanalyse mit Random-Effects-Modell; RRs und 95 %-KI in Stata. Risiko für Bias und Evidenzqualität wurden mit Cochrane RoB und CINeMA bewertet.
Ergebnisse
Primärer Wirksamkeitsendpunkt: rPA vs. rt-PA RR 1,13 (95 %-KI 1,06–1,19), TNK vs. rt-PA RR 1,04 (95 %-KI 1,00–1,08). Primärer Sicherheitsendpunkt: rhPro-UK vs. TNK RR 0,23 (95 %-KI 0,06–0,87).
Einschränkungen
Die Evidenz bildete ein sternförmiges Netzwerk ohne geschlossene Schleifen; direkte Head-to-head-RCTs fehlten.
Schlussfolgerung der Autor:innen
rPA und TNK waren mit besserer funktioneller Erholung als standardmäßiges rt-PA verbunden; rhPro-UK zeigte Potenzial zur Senkung des SICH-Risikos. Direkte randomisierte Vergleiche bleiben nötig.
Kernaussagen
- rPA besser als rt-PA für mRS 0–1 nach 90 Tagen
- TNK besser als rt-PA für mRS 0–1 nach 90 Tagen
- rhPro-UK senkte SICH gegenüber TNK
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 05.11.2026. Verfasst von Rufan Xu und 9 weiteren Autor:innen. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.
Themen: Schlaganfall
Abstract (Originalsprache)
Background
Intravenous thrombolysis (IVT) is the most important treatment for acute ischemic stroke (AIS) patients within 4.5 h of symptom onset, but the lack of head-to-head trials prevents comparisons of the IVT agents’ efficacy and safety, posing challenges for the selection of the best IVT agent. We aimed to evaluate all IVT agents’ effectiveness and safety in AIS treatment within 4.5 h of symptom onset.
Methods
We conducted a frequentist random-effects network meta-analysis to calculate relative risks (RRs) along with 95% confidence intervals (95% CI) using Stata. Between-study clinical and methodological heterogeneity was evaluated through pre-specified subgroup and sensitivity analyses; because the evidence formed a star-shaped network centered on alteplase (rt-PA) without closed loops, a consistency model was fitted. The primary efficacy outcome was excellent functional outcome (modified Rankin Scale [mRS] 0–1 at 90 days), and the primary safety outcome was symptomatic intracranial hemorrhage (SICH, ECASS III criteria) within 24–48 h. Secondary functional and safety outcomes were also evaluated. The risk of bias and the quality of evidence were assessed with the Cochrane Risk of Bias tool and the Confidence in Network Meta-Analysis tool.
Results
Nineteen RCTs involving 14,464 patients evaluated five IVT agents (rt-PA, tenecteplase [TNK], reteplase [rPA], recombinant human prourokinase [rhPro-UK], and staphylokinase [SAK]) and placebo. For primary efficacy outcome (mRS 0–1 at 90 days): SUCRA ranking was SAK (91.3%), rPA (83.8%), rhPro-UK (51.2%), TNK (50.5%), and rt-PA (23.2%). Compared with rt-PA, rPA significantly increased the likelihood of excellent recovery (RR 1.13, 95% CI: 1.06–1.19; high certainty), outperforming TNK (RR 1.09, 95% CI: 1.01–1.16; high certainty) and rhPro-UK (RR 1.08, 95% CI: 1.00–1.17; high certainty). TNK was also associated with a higher likelihood of excellent recovery compared with rt-PA (RR 1.04, 95% CI: 1.00–1.08; moderate certainty). For primary safety outcome (24–48 h SICH): SUCRA ranking for reducing bleeding risk was rhPro-UK (97.4%), rt-PA (56.5%), rPA (29.3%), and TNK (16.9%). rhPro-UK conferred a significantly lower risk of SICH compared with TNK (RR 0.23, 95% CI: 0.06–0.87; moderate certainty). No significant differences in SICH risk were detected among rPA, TNK, and rt-PA. No significant differences were observed across agents for 90-day all-cause mortality or any intracranial hemorrhage.
Conclusion
The rPA and TNK were associated with improved functional recovery compared with standard rt-PA, while rhPro-UK demonstrated potential in minimizing sICH risk, and direct head-to-head randomized trials remain needed.
Systematic review registration
PROSPERO, CRD42024615928.
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Xu, R., Li, N., Cheng, S., Lai, X., Zhang, H., Gao, Y., Qin, M., Liu, Z., Feng, L., & Gao, Y. (2026). Comparison of intravenous thrombolysis agents for acute ischemic stroke: a systematic review and network meta-analysis. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1884696
Vancouver
Xu R, Li N, Cheng S, Lai X, Zhang H, Gao Y, et al. Comparison of intravenous thrombolysis agents for acute ischemic stroke: a systematic review and network meta-analysis. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1884696
BibTeX
@article{Xu2026,
author = {Xu, Rufan and Li, Na and Cheng, Sisong and Lai, Xinxing and Zhang, Hongrui and Gao, Yonghong and Qin, Mingzhen and Liu, Zhenhong and Feng, Luda and Gao, Ying},
title = {Comparison of intravenous thrombolysis agents for acute ischemic stroke: a systematic review and network meta-analysis},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1884696}
}
EUVIMED